Expression Analysis of MiR-21, MiR-205, and MiR-342 in Breast Cancer in Iran
Expression Analysis of MiR-21, MiR-205, and MiR-342 in Breast Cancer in Iran
复制标题
DOI：
10.7314/apjcp.2012.13.3.873
复制
发表时间：
2012-01-01
影响因子：
--
通讯作者：
Modarressi, Mohammad Hossein
中科院分区：
文献类型：
--
作者：
Savad, Shahram;Mehdipour, Parvin;Modarressi, Mohammad Hossein
microRNA（miRNAs）是一类短的非编码RNA分子，其特征是在肿瘤和基因表达中起调控作用。我们分析了59例乳腺癌患者中miR-21、miR-205和miR-342的表达。根据其免疫组织化学（IHC）分类，将样品分为三个不同的组：ER阳性和/或PR阳性组（ER+和/或PR+; I组）; HER 2阳性组（HER 2（+）; II组）;和ER/PR/HER 2阴性（ER-/PR-/HER 2（-）; III组）作为三阴性组。分析3种miRNA在肿瘤样品中的表达水平，并与所有三组中的正常邻近解剖肿瘤（NNDT）样品进行比较。miR-21的表达在所有三组中相似。在免疫组化检测P53阳性、腋窝淋巴结转移阳性和肿瘤分期较高的患者中，P53的表达明显升高。然而，在18个纤维腺瘤样本中没有发现显著增加。miR-205和miR-342的表达在III组中均显著下调。我们得出结论，miR-21不能区分不同的乳腺癌组。相比之下，miR-205和miR-342可用作诊断三阴性乳腺癌的潜在生物标志物。
MicroRNAs (miRNAs) are short non-coding RNA molecules characterized by their regulatory roles in cancer and gene expression. We analyzed the expression of miR-21, miR-205, and miR-342 in 59 patients with breast cancer. Samples were divided into three different groups according to their immunohistochemistry (IHC) classification: ER-positive and/or PR-positive group (ER+ and/or PR+; group I); HER2-positive group (HER2(+); group II); and ER/PR/HER2- negative (ER-/PR-/HER2(-); group III) as the triple negative group. The expression levels of the 3 miRNAs were analyzed in the tumor samples and the compared with the normal neighboring dissected tumor (NNDT) samples in all three groups. The expression of miR-21 was similar in all three groups. In patients positive for P53 by IHC, positive for axillary lymph node metastasis and higher tumor stages, it appeared to have significantly elevated. However, significant increase was not found among the 18 fibroadenoma samples. Both miR-205 and miR-342 expressions were significantly down regulated in group III. We conclude that miR-21 does not discriminate between different breast cancer groups. In contrast, miR-205 and miR-342 may be used as potential biomarkers for diagnosis of triple negative breast cancer.